Cytomegalovirus Infection Treatment Market: By Drug Class, By Infection, By Distribution Channel and Region Forecast 2019-2030  

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Cytomegalovirus Infection Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Antiviral drugs, Foscarnet, Cytovene, Vistide, Others), By Infection (Retinitis, Pneumonia, Gastroenteritis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region Forecast 2019-2030  

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Cytomegalovirus infection treatment market size was valued at US$ 389.95 million in 2023 and is poised to grow at a CAGR of 4.8% from 2024-2030. Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease. Market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection.

Key Developments:

  • On December 21, 2023: Takeda announced that LIVTENCITY® (maribavir) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. LIVTENCITY is the first and only inhibitor of CMV-specific UL97 protein kinase in China for this indication. LIVTENCITY was granted Breakthrough Therapy Designation by China Center for Drug Evaluation (CDE) in 2021.
  • On June 06, 2023: Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved a new indication for PREVYMIS® (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]) following a priority review.

summary download arrow Download Free Sample

Global Cytomegalovirus Infection Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.8%

Largest Market

North-America

Fastest Growing Market

Europe

Cytomegalovirus Infection Treatment Market Dynamics

The cytomegalovirus treatment industry is predicted to increase substantially as the number of cases with CMV retinitis rises. CMV retinitis is a rather uncommon symptom of viral disease in other vulnerable groups. It is the earliest symptom of CMV infection in persons with AIDS. In up to 25% of AIDS patients, cytomegalovirus retinitis occurs. A symptom of CMV retinitis is necrotizing retinitis, which can cause retinal organisation and blindness.

CMV retinitis and other cytomegalovirus disease symptoms in HIV-1 patients are opportunistic infections that happen when CD4+ cell counts are extremely low. High-value-added active antiretroviral therapy will drive the market for CMV treatment. The global cytomegalovirus treatment market is being driven by the increased demand for CMV therapy due to the rising prevalence of cytomegalovirus retinitis in AIDS patients.

Global Cytomegalovirus Infection Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 389.95 million

Market CAGR

4.8%

By Drug Class

  • Antiviral drugs
    • Foscarnet
    • Cytovene
    • Vistide
    • Others

By Infection

  • Retinitis
  • Pneumonia
  • Gastroenteritis
  • Others (Mouth Ulcers, Pharyngitis, etc.)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The cytomegalovirus infection treatment market provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Cytomegalovirus Infection Treatment Market size is valued at US$ 389.95 million in 2023 and is poised to grow at a CAGR of 4.8% from 2024-2030.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

Chimerix, Clinigen Group PLC, Hoffmann-La Roche Ltd, Fresenius Kabi, Genentech Inc., Gilead Sciences, Merck & Co. Inc, Mylan N.V, Teva Pharmaceuticals Inc, Thermo Fisher Scientific, Takeda Pharmaceuticals, Pfizer

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Cytomegalovirus Infection Treatment Market Introduction 
2.1.Global Cytomegalovirus Infection Treatment Market  - Taxonomy
2.2.Global Cytomegalovirus Infection Treatment Market  - Definitions
2.2.1.Drug Class
2.2.2.Infection
2.2.3.Distribution channel
2.2.4.Region
3.Global Cytomegalovirus Infection Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Cytomegalovirus Infection Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Cytomegalovirus Infection Treatment Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Antiviral drugs
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
6.Global Cytomegalovirus Infection Treatment Market  By Infection, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Retinitis
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Pneumonia
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Gastroenteritis
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Cytomegalovirus Infection Treatment Market  By Distribution channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Cytomegalovirus Infection Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Cytomegalovirus Infection Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Antiviral drugs
9.2.  Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Retinitis
9.2.2.Pneumonia
9.2.3.Gastroenteritis
9.2.4.Others
9.3.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Cytomegalovirus Infection Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Antiviral drugs
10.2.  Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Retinitis
10.2.2.Pneumonia
10.2.3.Gastroenteritis
10.2.4.Others
10.3.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Cytomegalovirus Infection Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Antiviral drugs
11.2.  Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Retinitis
11.2.2.Pneumonia
11.2.3.Gastroenteritis
11.2.4.Others
11.3.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Cytomegalovirus Infection Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Antiviral drugs
12.2.  Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Retinitis
12.2.2.Pneumonia
12.2.3.Gastroenteritis
12.2.4.Others
12.3.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Cytomegalovirus Infection Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Antiviral drugs
13.2.  Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Retinitis
13.2.2.Pneumonia
13.2.3.Gastroenteritis
13.2.4.Others
13.3.  Distribution channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Chimerix
14.2.2.Clinigen Group PLC
14.2.3.Hoffmann-La Roche Ltd
14.2.4.Fresenius Kabi
14.2.5.Genentech Inc.
14.2.6.Gilead Sciences
14.2.7.Merck & Co. Inc
14.2.8.Mylan N.V
14.2.9.Teva Pharmaceuticals Inc
14.2.10.Thermo Fisher Scientific
14.2.11.Takeda Pharmaceuticals
14.2.12.Pfizer
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Chimerix
  • Clinigen Group PLC
  • Hoffmann-La Roche Ltd
  • Fresenius Kabi
  • Genentech Inc.
  • Gilead Sciences
  • Merck & Co. Inc
  • Mylan N.V
  • Teva Pharmaceuticals Inc
  • Thermo Fisher Scientific
  • Takeda Pharmaceuticals
  • Pfizer

Related Industry Reports

Global Infection Surveillance Solutions Market

Clostridium Difficile Infections disease Pipeline Drugs Assessment

Global Hepatitis B Virus Testing Market

Global Hepatitis C Virus Testing Market